|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01EM23
|
|
gptkbp:brand
|
gptkb:Aliqopa
|
|
gptkbp:CASNumber
|
1032754-93-6
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:hasMolecularFormula
|
C23H28N8O4
|
|
gptkbp:hasSMILES
|
CC1=CC(=O)N(C2=NC=NC(N3CCN(CC3)CCO)=N2)C4=CC=CC=C14
|
|
gptkbp:indication
|
relapsed follicular lymphoma after at least two prior therapies
|
|
gptkbp:KEGGID
|
gptkb:D10841
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:PI3K_inhibitor
|
|
gptkbp:molecularWeight
|
480.52 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105728
gptkb:DB12023
25154815
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
hypertension
leukopenia
hyperglycemia
pneumonitis
|
|
gptkbp:target
|
gptkb:PI3K-delta
gptkb:PI3K-alpha
|
|
gptkbp:UNII
|
8Y6I1W0A1I
|
|
gptkbp:usedFor
|
treatment of follicular lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Class_I_PI3K
gptkb:PIK3CA
gptkb:PIK3CD
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
copanlisib
|